1 Secondary end points were 5-year locoregional control and dis
2 Secondary end points were 5-year locoregional failure, overal
3 Key
secondary end points were 90-day mortality, kidney replacemen
4 Secondary end points were a 50% or greater reduction in mean
5 Key
secondary end points were absolute changes from baseline in t
6 Secondary end points were all-cause mortality and ICD-related
7 The primary end point was cardiovascular events;
secondary end points were all-cause mortality, ventricular ar
8 Primary and
secondary end points were assessed in a hierarchic model to c
9 Secondary end points were best ORR during the first 6 months,
10 Secondary end points were biochemical, histologic, and imagin
11 Secondary end points were bleeding and INR values of 4 or mor
12 Secondary end points were change in 6-minute walk distance, p
13 he primary end point was the safety and tolerability, while
secondary end points were clinical outcomes (relapses and dis
14 All prespecified
secondary end points were consistently improved in the 300 IR
15 Secondary end points were cutaneous reactivity and serum IgE
16 Primary and
secondary end points were disease-free survival (DFS) and ove
17 Secondary end points were duration of response, disease contr
18 Key
secondary end points were duration of response, progression-f
19 ely 240 deaths had occurred, overall survival and all other
secondary end points were evaluated.
20 Secondary end points were frequency of infections, treatment-
21 The differences in
secondary end points were generally in the same direction as
22 Secondary end points were improvement in fibrosis (reduction
23 The main outcome was incident HF after visit 5, and key
secondary end points were incident HF with preserved LVEF (HF
24 Secondary end points were locoregional control, local control
25 The primary end point was PFS;
secondary end points were OS, toxicity, and the appearance of
26 The primary end point was disease-free survival (DFS);
secondary end points were overall survival (OS) and safety.
27 Main
secondary end points were overall survival and bronchiolitis
28 Secondary end points were patient-reported outcomes, tolerabi
29 Secondary end points were patient-reported toxicity, overall
30 Secondary end points were patients alive without events (AWE)
31 change in photographic breast appearance at 2 and 5 years;
secondary end points were physician assessments of NTE and lo
32 nd-point was the rate of tumor-free resection margins (R0);
secondary end-points were postoperative complications and mor
33 Secondary end points were progression-free survival (PFS), ob
34 Primary end point was overall survival (OS), and
secondary end points were progression-free survival (PFS), re
35 Secondary end points were progression-free survival, DCR, OS,
36 Secondary end points were PSA, surgical staging, positive mar
37 The primary and other key
secondary end points were reported previously.
38 Secondary end points were rescue neuroleptic use, delirium re
39 Key
secondary end points were response and mucosal healing (centr
40 Key
secondary end points were response by International Workshop
41 Secondary end points were response rate, 3-year locoregional
42 Secondary end points were standardized area under the curve o
43 None of the 3 prespecified
secondary end points were statistically significant.
44 The key
secondary end points were T-cell persistence and their antigl
45 Secondary end points were the change in the mean number of mu
46 ange in LDL cholesterol level from baseline to week 24; key
secondary end points were the mean percent change in LDL chol
47 Secondary end points were the number of telephone calls and e
48 Secondary end points were the scores for working memory (scor
49 Secondary end points were treatment exposure and change in ce
50 Secondary end points were treatment response (>30% reduction